282.10
+0.64%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Advanced Enzyme Technologies
Its shares trade on NSE under the ticker ADVENZYMES.NS. It has been listed since 1 August 2016. In the fiscal year to 31 March 2026, it reported revenue of ₹7.46bn and net income of ₹1.69bn. At that date it held total assets of ₹18.39bn and shareholders' equity of ₹16.32bn.
Advanced Enzyme Technologies Ltd. engages in the research, development, manufacture, and sale of enzyme products. The company is headquartered in Thane, Maharashtra. The company went IPO on 2016-08-01. The firm is focused on the research and development, manufacturing, and marketing of approximately 400 products, which is developed from over 68 indigenous enzymes and probiotics. The company provides solutions to various industries, such as human health care and nutrition, animal nutrition, baking, fruit, and vegetable processing, brewing, and malting, grain processing, protein modification, dairy processing, textile processing and others. The company offers products and solutions for human nutrition, which include serratiopeptidase, fungal lactase, fungal lipase, and papain; animal nutrition, which include DigeGrain X, DigeGrain XL and DigeGrain M; food processing, including dairy and cheese processing and yeast processing, and non-food processing, including textiles processing, leather, and biofuels. Its oils and fats processing include oil extraction, oil refining, and others.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Materials
- Industry
- Chemicals
- Listed since
- 1 Aug 2016
- Employees
- 338
- Website
- advancedenzymes.com ↗
Leadership
Pay as last reported
- Mr. Vasant RathiNon-Executive Chairman of the Board, since 2020₹990,000
- Mr. Beni RaukaChief Financial Officer
- Mr. Dipak RodaSenior Vice President - Business Development, Marketing, since 2021
- Mr. Mukund KabraWhole Time Director, since 2017₹31.4m
- Ms. Martina DoeringManaging Director and Head Of Business Development, Evoxx Technologies GmbH, Germany
- Mr. Harshad DoshiChief Financial Officer and Chief Operating Officer of the US Subsidiaries
- Dr. Michael PulsManaging Director and Head Of Research and Development, Evoxx Technologies GmbH, Germany
- Mr. Sanjay BasantaniCompany Secretary and Head Legal
- Ms. Rasika RathiNon-Executive Director₹590,000
- Dr. Sunny SharmaNon-Executive Director₹300,000
- Mr. Nitin DeshmukhIndependent Director₹810,000
- Mr. Vinodkumar JajooIndependent Director₹1.4m
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 72
- Environment
- 64
- Social
- 71
- Governance
- 81
- Women in the workforce
- 18.63905%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Advanced Enzyme Technologies Ltd develops 400 products from 68 indigenous enzymes and probiotics.
- The company provides solutions for human health care, animal nutrition, and food processing industries.
- Advanced Enzyme Technologies Ltd employs 338 full-time employees in Thane, Maharashtra.
Weaknesses
- The company's business is limited to 400 products developed from 68 indigenous enzymes and probiotics.
- Advanced Enzyme Technologies Ltd has no mention of international expansion in its business description.
- The company's focus on indigenous enzymes may restrict product diversity compared to global competitors.
Opportunities
- The growing demand for enzyme solutions in human health care and animal nutrition sectors presents opportunities.
- Advanced Enzyme Technologies Ltd can expand its product range in the food processing industry.
- The company can leverage its 68 indigenous enzymes to enter new markets like biofuels and textiles.
Threats
- The company faces competition from global enzyme manufacturers in the Materials sector.
- Advanced Enzyme Technologies Ltd must comply with evolving regulations in the Chemicals industry.
- The company's reliance on indigenous enzymes could be a threat if supply chains are disrupted.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.